Genetic Analysis has announced a Service Agreement with Eurofins ADME Bioanalysis, a CRO who have launched a standardised gut microbiome test (GA-map Dysbiosis Test).
Gut microbiome profiling is required as a surrogate endpoint or exploratory biomarker in clinical trials. This is due to both the impact new pharmaceuticals can have on microbiomes and the fact that the microbiota composition itself may greatly affect the response to treatment.
Genetic Analysis profiles and compares an imbalanced microbiota to healthy references. The standardised GA-map Test is based on a pre-determined targets approach (PDT) and is a tool in drug development, clinical research and routine diagnostics.
Ronny Hermansen, CEO of Genetic Analysis, said: “Genetic Analysis is proud to have Eurofins ADME Bioanalysis as a partner in the clinical research field. To map and unlock the bacteria present in the gut is instrumental for developing better treatment regimes. The GA-map platform will offer a fast turnaround lab testing service with an integrated software algorithm for immediate result presentation.”
